[go: up one dir, main page]

MXPA06011467A - Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). - Google Patents

Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).

Info

Publication number
MXPA06011467A
MXPA06011467A MXPA06011467A MXPA06011467A MXPA06011467A MX PA06011467 A MXPA06011467 A MX PA06011467A MX PA06011467 A MXPA06011467 A MX PA06011467A MX PA06011467 A MXPA06011467 A MX PA06011467A MX PA06011467 A MXPA06011467 A MX PA06011467A
Authority
MX
Mexico
Prior art keywords
active substance
substance combination
nsaid
carbinol
combined
Prior art date
Application number
MXPA06011467A
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Jorg Holenz
Bonifacio Gutierrez Silva
Antonio Farre Gomis
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Priority claimed from PCT/EP2005/003641 external-priority patent/WO2005097099A1/en
Publication of MXPA06011467A publication Critical patent/MXPA06011467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se relaciona con una combinacion de sustancias activas que comprende al menos un compuesto de carbinol sustituido y al menos un farmaco antiinflamatorio no esteroide (NSAID), un medicamento que comprende la combinacion de sustancias activas, una formulacion farmaceutica que comprende la combinacion de sustancias activas y para la elaboracion de un medicamento.
MXPA06011467A 2004-04-05 2005-04-05 Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid). MXPA06011467A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200400844A ES2244326B1 (es) 2004-04-05 2004-04-05 Combinacion de substancias activas.
US10/987,803 US20050222136A1 (en) 2004-04-05 2004-11-12 Active substance combination
PCT/EP2005/003641 WO2005097099A1 (en) 2004-04-05 2005-04-05 Active substance combination comprising a carbinol combined to at least an nsaid

Publications (1)

Publication Number Publication Date
MXPA06011467A true MXPA06011467A (es) 2007-06-12

Family

ID=35148893

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011467A MXPA06011467A (es) 2004-04-05 2005-04-05 Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).

Country Status (4)

Country Link
US (2) US20050222136A1 (es)
CN (1) CN101031291A (es)
ES (1) ES2244326B1 (es)
MX (1) MXPA06011467A (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
CN101600458A (zh) * 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
WO2008146178A2 (en) * 2007-05-30 2008-12-04 Wockhardt Research Centre A novel tablet dosage form
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
JP2013520681A (ja) * 2010-02-24 2013-06-06 バイオデシックス・インコーポレイテッド 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション
TWI572600B (zh) * 2013-01-10 2017-03-01 Konica Minolta Inc 樹脂組成物、三唑化合物、光學薄膜、偏光板、光學透鏡、圓偏光板、及圖像顯示裝置
CA2903612C (en) * 2013-03-13 2021-03-30 Canadian Blood Services Pyrazole derivatives and their uses thereof
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
CN112603901A (zh) * 2020-12-02 2021-04-06 成都锦华药业有限责任公司 一种奥沙普秦肠溶微丸、药剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US641582A (en) * 1899-08-28 1900-01-16 John F Kerr Jacquard-machine for looms.
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
ES2130079B1 (es) * 1997-07-10 2000-01-16 Esteve Labor Dr Resolucion de aminas
ES2130083B1 (es) * 1997-08-04 2000-01-16 Esteve Labor Dr Procedimiento para la obtencion de los enantiomeros de cizolirtina.
ES2150378B1 (es) * 1998-08-07 2001-07-01 Esteve Labor Dr Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
WO2005043114A2 (en) * 2003-10-22 2005-05-12 Ron Broide Oligonucleotide probe sets and uses thereof
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
US20060040924A1 (en) * 2004-06-22 2006-02-23 Laboratorios Dr. Esteve S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic
EP1671953A1 (en) * 2004-12-17 2006-06-21 Laboratorios Del Dr. Esteve, S.A. Process for obtaining cizolirtine and its enantiomers
EP1671968A1 (en) * 2004-12-17 2006-06-21 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of thienylazolylalcoxyethanamines
EP1674465A1 (en) * 2004-12-27 2006-06-28 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of thienylazolylalcoxyethanamines

Also Published As

Publication number Publication date
US20070088024A1 (en) 2007-04-19
ES2244326B1 (es) 2007-02-16
US20050222136A1 (en) 2005-10-06
CN101031291A (zh) 2007-09-05
ES2244326A1 (es) 2005-12-01

Similar Documents

Publication Publication Date Title
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
MX2009010289A (es) Composiciones para administracion nasal.
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
AU2008347158A8 (en) Oral pharmaceutical dosage forms
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EA201001857A1 (ru) Фармацевтическая лекарственная форма для немедленного высвобождения производного индолинона
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
CO6321158A2 (es) Formulacion oral
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
ATE366105T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2005117895A8 (en) Compositions comprising meloxicam
DK1359939T3 (da) Sammensætning og fremgangsmåde til potensering af lægemidler
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
NO20064808L (no) Orale matrixformuleringer med licarbazepin
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.